Abbreviations: 1,3 Phenylenediamine dihydrochloride (mPD); alpha 7 nicotinic acetylcholine receptor (α7nAChR); alpha bungarotoxin (aBTx); Alzheimer's disease (AD); amyloid beta (Aβ); analysis of variance (ANOVA); L-ascorbic acid (AA); bovine serum albumin (BSA); dentate gyrus (DG); dopamine hydrochloride (DA); Fast Analytical Sensing Technology (FAST); hydrogen peroxide (H2O2); microelectrode array (MEA); phosphate buffered saline (PBS); platinum (Pt); standard error of the mean (SEM); tetrodotoxin (TTX) 2 Abstract Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss and hippocampal atrophy. Soluble amyloid-β (Aβ)42 and plaque accumulation is implicated as the neurotoxic species in this disorder, however, at physiological concentrations (pM-nM), Aβ42 contributes to neurogenesis, long-term potentiation, and neuromodulation. Because Aβ42 binds the α7 nicotinic acetylcholine receptors (α7nAChRs) located presynaptically on glutamatergic terminals, involved with hippocampal dependent learning and memory, we examined the effects of the human, monomeric isoform of Aβ42 on glutamate release in the dentate gyrus (DG), CA3, and CA1, of isoflurane anesthetized, 6-9 month old male C57BL/6J mice.
Introduction
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by progressive memory loss, cognitive decline, and hippocampal atrophy. The hallmark pathological features of AD includes amyloid-β (Aβ) plaques and neurofibrillary tangles with evidence supporting abnormal accumulation of Aβ followed by tau-mediated neuronal injury and dysfunction [1] . This process, referred to as the amyloid cascade hypothesis, proposes that Aβ initiates the series of pathological events leading to neuronal dysfunction, cell death, and the eventual cognitive impairments observed in AD [2] . In AD brains, Aβ40 and Aβ42 are the predominant peptide isoforms, the latter of which is believed to aggregate faster and thusly considered more neurotoxic [3] . For example, recent evidence supports soluble Aβ42 dimers as the neurotoxic isoform precipitating AD pathology [4] [5] [6] .
However, at physiological concentrations (pM-nM) experimental evidence suggests Aβ has a role in normal brain functions including neurogenesis, long-term potentiation, and neurotransmitter modulation [7] [8] [9] . Aβ42 binds to the α7 nicotinic acetylcholine receptor (α7nAChR) with picomolar affinity [10] and activation of this receptor is known to stimulate glutamate release [11] . Glutamate, the predominant excitatory neurotransmitter in the mammalian CNS, has a strong prevalence in neocortical and hippocampal pyramidal neurons and, therefore, plays a critical role in learning and memory [12] . Furthermore, picomolar concentrations of Aβ42 can enhance synaptic plasticity and reference memory through activation of the α7nAChR [13] . These data suggest that endogenous Aβ42 formation lies on a continuum whereby low concentrations of the peptide are important for normal brain function, however, when a concentration threshold is crossed; accumulation and aggregation dominate leading to neurotoxicity [7] .
The purpose of the present study was to elucidate whether Aβ42 could evoke hippocampal glutamate release through the α7nAChR.
Because of the rapid (msec) clearance of glutamate from the extracellular space by the high-affinity excitatory amino acid transporters [14, 15] few studies have been capable of directly measuring glutamatergic neurotransmission on a subsecond timescale. To do this, we utilized an enzyme-based microelectrode array (MEA) coupled with constant potential amperometry to independently measure glutamate release in the dentate gyrus (DG), CA3, and CA1 of isoflurane anesthetized C57BL/6J mice. These MEAs have fast temporal (4 Hz) [16] , low spatial (50 x 100 µm) resolution and minimal damage to the surrounding parenchyma (50-100 microns) [17] . A glass micropipette was attached to the MEA to locally apply varying concentrations of Aβ42 (0.01 -10.0 µM). While standard practice is to report the concentration of solutions in the glass micropipette, it should be noted that pressure ejection of solutions from a micropipette in vivo act as a point source with the concentration decreasing as the distance increases from the ejection site [18] . We have determined that a tenth of the barrel concentration is diffusing to the MEA surface, which is considered further in the discussion section.
The results presented here support the ability of soluble Aβ42 to stimulate the α7nAChR leading to glutamate release that varies among hippocampal subfields.
Materials & Methods
Animals: Six to nine month-old, male C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME). Protocols for animal use were approved by the Laboratory Animal Care and Use Committee at Southern Illinois University School of Medicine. Animals were group housed on a 12:12 hour light: dark cycle, and food and water were available ad libitum. Immediately following experimentation, mice were euthanized with an overdose of isoflurane and decapitated. Brains were fixed in 4% paraformaldehyde for histological assessment of MEA placement.
Chemicals: All chemicals were prepared and stored according to manufacturer recommendations unless otherwise noted. Human Enzyme-Based Microelectrode Arrays: Enzyme-based MEAs with platinum (Pt) recording surfaces ( Figures 1A & B) were fabricated, assembled, coated, and calibrated for in vivo mouse glutamate measurements as previously described [19] [20] [21] . Briefly, one of the R2 MEA Pt sites was coated with an L-glutamate oxidase, BSA, glutaraldehyde coating solution. BSA and glutaraldehyde increase the adhesion and crosslink L-glutamate oxidase to the MEA surface. L-glutamate oxidase enzymatically degrades glutamate to α-ketoglutarate and the electroactive reporter molecule, H2O2. The second Pt recording site (self-referencing or sentinel site) was coated similar to the glutamate recording site, except L-glutamate oxidase was omitted from the coating solution; therefore, unable to enzymatically generate H2O2 from L-glutamate. A potential of +0.7 V vs a Ag/AgCl reference electrode was applied to the Pt recording surface, resulting in a two electron oxidation of H2O2 and the current was amplified and digitized by the Fast Analytical Sensing Technology (FAST) 16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.
mPD Electropolymerization: A minimum of 72 hrs after enzyme coating, Pt recording surfaces were electroplated with 5 mM mPD in 0.05 M phosphate buffered saline (PBS) [22] . FAST electroplating software applied a triangular wave potential with a -0.5 V offset and 0.25 V peak-to-peak amplitude at 0.05 Hz for 20 min to create an exclusion layer that restricts the passage of AA, DA, uric acid, and 3,4-dihydroxyphenylacetic acid.
Calibration: A minimum of 24 hrs after mPD electropolymerization, each MEA was calibrated prior to implantation to generate a standard curve for the conversion of current to glutamate concentration [23] . Chicago, IL) and the other was coated with AgCl by placing the tip of the sliver wire (cathode) into a 1 M HCl plating bath saturated with NaCl containing a stainless steel wire (anode) and applying +9 V DC using a power supply to the cathode vs the anode for 15 min.
In Vivo Anesthetized Recordings: Mice were anesthetized using 1.5-2.0% isoflurane (Abbott Lab, North Chicago, IL) in a calibrated vaporizer (Vaporizer Sales & Service, Inc., Rockmart, GA) and prepared for in vivo electrochemical recordings as described elsewhere [20] . The mouse was placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) fitted with a mouse anesthesia mask and body temperature was maintained at 37°C with a water pad connected to a recirculating water bath. A craniotomy was performed to access the hippocampus. The Ag/AgCl reference wire was remotely implanted in the right cortex. Using a microdrive (Narishige International, East Meadow, NY) attached to the electrode holder of the stereotaxic arm, the MEA / micropipette assembly was lowered into the DG (AP: -2.0, ML: ± 1.0, DV: -2.2 mm), CA3 (AP: -2.0, ML: ± 2.0, DV: -2.2 mm) and CA1 (AP: -2.0, ML: ± 1.0, DV: -1.7 mm), from Bregma that was randomly assigned for each mouse [25] . Each hemisphere was randomly assigned to a different treatment group to minimize the number of mice used. Constant voltage amperometry (4 Hz) was performed using the FAST16mkIII and FAST software for multi-channel simultaneous recordings [26] . MEAs were allowed to reach a stable baseline for 60 min before basal glutamate determination and pressure ejection studies. 
Results
We characterized the Aβ42 peptide conformation by using gel electrophoresis methods. With SDS-PAGE, the preparations analyzed resolved to a 4.5 kDA species consistent with the monomeric isoform that was visible at the 10.0, 1.0, and 0.1 µM Aβ42 concentrations ( Figure S1 ). However, the lowest concentrations of Aβ42 (0.01 and 0.001 µM) resulted in undetectable levels.
Basal Glutamate
Prior to local application studies, basal glutamate measures were assessed. Basal glutamate was similar among the DG (1.5 ± 0.3 µM; n=30), CA3 (2.0 ± 0.3 µM; n=31), and CA1 (1.9 ± 0.3 µM; n=29) hippocampal subfields as shown in Figure 2 . Sample size refers to the number of animals in each hippocampal subfield.
Local application of Aβ42
We locally applied similar volumes ( Figure 3A 
Discussion
The data presented in this manuscript indicates that local application of monomeric soluble Aβ42 evokes glutamate release through the α7nAChR in all three hippocampal subfields studied. Magdesian and colleagues [30] have demonstrated that Aβ binds at the interface between the acetylcholine and nicotine binding domains of the α7nAChR. Additionally, Aβ-evoked Ca 2+ efflux from nerve terminals was not increased after coapplication of nicotine suggesting similar binding sites [31, 32] . Since nicotine has been shown to evoke glutamate release via the α7nAChR [11] , these studies support Aβ42 binding near the nicotinic site on α7nAChR to evoke glutamate release.
Conflicting data exists in the literature regarding the α7nAChR-Aβ interaction with studies supporting both receptor activation and inhibition [33] . These differences may be related to the model system employed as well as the aggregation state and concentration of Aβ used. We selected the anesthetized mouse as our model system since this provides us with the complete hippocampal afferent / efferent connections as well as contribution from astrocytes (glutamate uptake and/or gliotransmission). Using SDS-PAGE we have confirmed that we are locally applying the monomeric isoform of Aβ42. Finally the concentration of Aβ is the largest confounding variable in the literature. Physiological concentrations of Aβ (pM to low nM) have been shown to potentiate neurotransmitter release while supraphysiological concentrations (high nM to µM) inhibit neurotransmitter release [8] . While standard practice is to report the concentration of solutions in the glass micropipette, it should be noted that pressure ejection of solutions from a micropipette in vivo act as a point source with the concentration decreasing as the distance increases from the ejection site [18] . in glutamate release are observed in the CA1 [16] and DG (unpublished observations). These data are consistent with the concept that physiological concentrations of Aβ modulate neurotransmitter release essential for synaptic plasticity and learning and memory [7, 13] .
The most striking results from this study are the differences in Aβ42-evoked glutamate release among the hippocampal subfields. The largest glutamate responses were observed with 0.1 µM Aβ42 in the DG and CA1, while 10.0 µM produced a slightly larger glutamate response in the CA3. These discrepancies might be attributable to the distribution of α7nAChR in the rodent hippocampus.
Autoradiographic studies indicate αBTx binding sites are slightly weaker in the CA3 compared to the DG and CA1 subfields [35] . Fewer CA3 α7nAChRs may help to explain why the highest concentration of Aβ42 tested evoked the largest release of glutamate in this hippocampal subfield. Interestingly, Aβ protein deposition in humans with AD has been shown to occur first in the CA1 and DG followed by the CA3 [36] , similar to the pattern we observed with increased Aβ42-evoked glutamate release at lower concentrations in the CA1 and DG. Regardless, the demonstration of Aβ42-evoked glutamate release differences among the DG, CA3, and CA1 supports the need to utilize in vivo recording techniques with high spatial resolution to be able to independently measure discrete subregions of larger anatomical CNS structures.
While our current studies support Aβ42-evoked glutamate release is completely modulated through the α7nAChR, Aβ42 can bind the α4β2nAChR at 100-5000 times higher concentration than α7nAChR [10] . Furthermore, Mura and colleagues [8] reported Aβ had a dual effect on the α7 and α4β2nAChR in the rat hippocampus. The biggest difference between these two studies was that Mura and colleagues conducted their experiments in awake, freely-behaving rats while our studies were performed in isoflurane anesthetized mice. Isoflurane has been shown to inhibit the α4β2, but not α7nAChR [37] . Based on these data, we cannot rule out a potential role for the α4β2 nAChR-Aβ42 modulation of glutamate release.
Gahring and colleagues [38] have demonstrated that α7nAChR are located on both neurons and astrocytes, however the role of glial α7nAChR in glutamate release is unclear. For example, stimulation of astrocytic α7nAChR by nicotine has resulted in the release of glutamate from mouse cortical gliosomes [39] , but Salamone and colleagues reported that perfusion of Aβ40 onto rat hippocampal gliosomes inhibited glutamate overflow [40] , which may result in decreased basal glutamate. Since the present studies support that Aβ42 evokes glutamate release in vivo, we sought to determine the neuronal versus glial contribution by coapplying 0.1 µM Aβ42 with 10.0 µM TTX. TTX is a reversible sodium channel blocker that prevents neuronal depolarization, while gliotransmission, the result of increased astrocytic intracellular calcium levels, would be unaffected. In the present study, coapplication of 0.1 µM Aβ42 with 10.0 µM TTX completely blocked Aβ42 mediated glutamate release and decreased basal glutamate levels as previously observed [27, 41, 42] , supporting Aβ42-evoked glutamate release originating from predominantly neuronal activation of the α7nAChR. Furthermore, by blocking neuronal depolarization with TTX, the coapplied Aβ42 could still bind astrocytic α7nAChR and synergistically depress basal glutamate. This may suggest a dual role for the α7nAChR whereby binding evokes neuronal glutamate release but blocks astrocytic glutamate release.
While excitotoxicity has been proposed as a mechanism of neuronal death and cognitive decline associated with AD [43] , the concentration of Aβ42-evoked glutamate release observed in this study is not in the neurotoxic range for an intact CNS abundant in glia under normal conditions [15] . Rather, the progressive accumulation of Aβ42 during disease progression could lead to persistent activation of the α7nAChR and chronically elevate glutamate release that, over time, results in excitotoxicity. Soluble Aβ42 levels have been shown to increase during AD progression in both humans [44, 45] and mouse models of AD [34, 46] . Furthermore, Aβ42 causes protein oxidation of glutamine synthetase [47] and glutamate transporter 1 [48] , the predominant isoform that accounts for ~90% of glutamate clearance from the extracellular space. As the soluble Aβ42 concentration gradually increases, its neuromodulatory role on glutamate release is elevated while simultaneously decreasing glutamate clearance resulting in excitotoxicity, thereby initiating the cognitive decline associated with AD.
Furthermore, as the Aβ42 concentration increases from a physiological neuromodulatory role to the pathological hallmark observed in AD, the α7nAChR-Aβ42 interaction may advance AD etiology through several mechanisms. First, prolonged exposure to high nM concentrations of Aβ42 has been shown to block or desensitize α7nAChR receptor function thereby preventing the normal function of these receptors [49] . Second, the α7nAChR-Aβ42 complex may become internalized in both neurons and astrocytes, leading to plaque formation and eventual host cell lysis and plaque deposition [50] . Third, the α7nAChR-Aβ42 may serve as the initial scaffold for Aβ42 aggregation and eventual plaque accumulation [10] resulting in AD neuropathological progression [36] as previously mentioned. Taken together, these data suggest that Aβ42 accumulation causes a functional blockade of the α7nAChR that impairs neuromodulation and potentially cognition, which may support why drugs targeting the cholinergic and glutamatergic systems in later stages of AD are largely unsuccessful.
In conclusion, we have demonstrated that soluble, monomeric Aβ42 can evoke glutamate release through the α7nAChR and release varies across hippocampal subfields. This release is mediated through a sodium channel dependent mechanism. Future studies will determine if dimeric and trimeric isoforms of Aβ42-evoke or -inhibit glutamate release and determine the potential receptors through which these mechanisms occur. 
